News Abliva AB

Equities

ABLI

SE0002575340

Delayed Nasdaq Stockholm Other stock markets 10:36:08 2024-04-24 am EDT			5-day change	1st Jan Change
0.1648 ^SEK	-2.49%		+0.86%	-32.87%

Feb. 23	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abliva AB Publishes 2023 Annual Report	08:50am	AQ
Notice of Annual General Meeting of Abliva AB (publ)	Apr. 22	AQ
Abliva publishes rights issue outcome	Apr. 19	AQ
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	Apr. 08	AQ
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	Mar. 27	AQ
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	Mar. 26	AQ
BioStock: Abliva's CEO comments on the proposed capital raise	Feb. 29	AQ
Abliva AB Year-End Report January – December 2023	Feb. 23	AQ
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 23	CI
Notice of Extraordinary General Meeting of Abliva AB (publ)	Feb. 22	AQ
The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study	Feb. 22	AQ
BioStock: Abliva reaches enrollment goal	Dec. 21	AQ
Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	Dec. 20	AQ
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	Dec. 20	CI
BioStock: Abliva's CEO: "Orphan drug designation is great validation"	Dec. 15	AQ
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	Dec. 14	MT
Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354	Dec. 14	AQ
Abliva AB Interim Report January – September 2023	Nov. 17	AQ
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
BioStock: Abliva signs global license deal for NeuroSTAT	Nov. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Abliva AB

Equities

ABLI

SE0002575340

Summary

Filters